European Heart Journal

The increasing use of single-cell immune profiling and advanced microscopic imaging technologies has deepened our understanding of the cardiac immune system, confirming that the heart contains a broad repertoire of innate and adaptive immune cells. Leucocytes found in the healthy heart participate in essential functions to preserve cardiac homeostasis, not only by defending against pathogens but also by maintaining normal organ function. In pathophysiological conditions, cardiac inflammation is implicated in healing responses after ischaemic or non-ischaemic cardiac injury. The aim of this review is to provide a concise overview of novel methodological advancements to the non-expert readership and summarize novel findings on immune cell heterogeneity and functions in cardiac disease with a focus on myocardial infarction as a prototypic example. In addition, we will briefly discuss how biological sex modulate the cardiac immune response. Finally, we will highlight emerging concepts for novel therapeutic applications, such as targeting immunometabolism and nanomedicine.

خرید پکیج و مشاهده آنلاین مقاله

Management of acute coronary syndromes in older adults

Nuccia Morici, Stefano De Servi, Leonardo De Luca, Gabriele Crimi, Claudio Montalto, Roberta De Rosa, Giuseppe De Luca, Andrea Rubboli, Marco Valgimigli, Stefano Savonitto

doi : 10.1093/eurheartj/ehab391

European Heart Journal, Volume 43, Issue 16, 21 April 2022, Pages 1542â€“1553

Older patients are underrepresented in prospective studies and randomized clinical trials of acute coronary syndromes (ACS). Over the last decade, a few specific trials have been conducted in this population, allowing more evidence-based management. Older adults are a heterogeneous, complex, and high-risk group whose management requires a multidimensional clinical approach beyond coronary anatomic variables. This review focuses on available data informing evidence-based interventional and pharmacological approaches for older adults with ACS, including guideline-directed management. Overall, an invasive approach appears to demonstrate a better benefitâ€“risk ratio compared to a conservative one across the ACS spectrum, even considering patientsâ€™ clinical complexity and multiple comorbidities. Conversely, more powerful strategies of antithrombotic therapy for secondary prevention have been associated with increased bleeding events and no benefit in terms of mortality reduction. An interdisciplinary evaluation with geriatric assessment should always be considered to achieve a holistic approach and optimize any treatment on the basis of the underlying biological vulnerability.

خرید پکیج و مشاهده آنلاین مقاله

Alirocumab after acute coronary syndrome in patients with a history of heart failure

Harvey D White, Gregory G Schwartz, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Chern-En Chiang, Rafael Diaz, Shaun G Goodman, Johan Wouter Jukema, Megan Loy, Neha Pagidipati, Robert Pordy, Arsen D RistiÄ‡, Andreas M Zeiher, Daniel M Wojdyla, Philippe Gabriel Steg, for the ODYSSEY OUTCOMES Investigators

doi : 10.1093/eurheartj/ehab804

European Heart Journal, Volume 43, Issue 16, 21 April 2022, Pages 1554â€“1565

Patients with heart failure (HF) have not been shown to benefit from statins. In a post hoc analysis, we evaluated outcomes in ODYSSEY OUTCOMES in patients with vs. without a history of HF randomized to the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab or placebo.

خرید پکیج و مشاهده آنلاین مقاله

PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?

Alexander Niessner, Heinz Drexel

doi : 10.1093/eurheartj/ehab913

European Heart Journal, Volume 43, Issue 16, 21 April 2022, Pages 1566â€“1568

خرید پکیج و مشاهده آنلاین مقاله

Targeted proteomics improves cardiovascular risk prediction in secondary prevention

Nick S. Nurmohamed, JoÃ£o P. Belo Pereira, Renate M. Hoogeveen, Jeffrey Kroon, Jordan M. Kraaijenhof, Farahnaz Waissi, Nathalie Timmerman, Michiel J. Bom, Imo E. Hoefer, Paul Knaapen, Alberico L. Catapano, Wolfgang Koenig, Dominique de Kleijn, Frank L.J. Visseren, Evgeni Levin, Erik S.G. Stroes

doi : 10.1093/eurheartj/ehac055

European Heart Journal, Volume 43, Issue 16, 21 April 2022, Pages 1569â€“1577

Current risk scores do not accurately identify patients at highest risk of recurrent atherosclerotic cardiovascular disease (ASCVD) in need of more intensive therapeutic interventions. Advances in high-throughput plasma proteomics, analysed with machine learning techniques, may offer new opportunities to further improve risk stratification in these patients.

خرید پکیج و مشاهده آنلاین مقاله

Proteomics for the prediction and prevention of atherosclerotic disease

Paul M. Ridker

doi : 10.1093/eurheartj/ehac036

European Heart Journal, Volume 43, Issue 16, 21 April 2022, Pages 1578â€“1581

خرید پکیج و مشاهده آنلاین مقاله

Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis

Mihir A Kelshiker, Henry Seligman, James P Howard, Haseeb Rahman, Michael Foley, Alexandra N Nowbar, Christopher A Rajkumar, Matthew J Shun-Shin, Yousif Ahmad, Sayan Sen, Rasha Al-Lamee, Ricardo Petraco

doi : 10.1093/eurheartj/ehab775

European Heart Journal, Volume 43, Issue 16, 21 April 2022, Pages 1582â€“1593

This meta-analysis aims to quantify the association of reduced coronary flow with all-cause mortality and major adverse cardiovascular events (MACE) across a broad range of patient groups and pathologies.

خرید پکیج و مشاهده آنلاین مقاله

Coronary flow reserve: a versatile tool for interrogating pathophysiology, and a reliable marker of cardiovascular outcomes and mortality

Viviany R Taqueti

doi : 10.1093/eurheartj/ehac001

European Heart Journal, Volume 43, Issue 16, 21 April 2022, Pages 1594â€“1596

خرید پکیج و مشاهده آنلاین مقاله

Reduction of lipoprotein(a) with proprotein convertase subtilisin/kexin type 9 inhibitor as a potential contributor to modulating coronary inflammatory activity: insights from serial pericoronary adipose tissue analysis

Satoshi Kitahara, Yu Kataoka, Hiroyuki Miura, Teruo Noguchi

doi : 10.1093/eurheartj/ehab882

European Heart Journal, Volume 43, Issue 16, 21 April 2022, Page 1597

خرید پکیج و مشاهده آنلاین مقاله

Cerebral protection device out of transcatheter heart procedures: a bridge to surgery

Simone Calcagno, Riccardo Di Pietro, Giuseppe Biondi-Zoccai, Francesco Versaci

doi : 10.1093/eurheartj/ehab915

European Heart Journal, Volume 43, Issue 16, 21 April 2022, Page 1598

خرید پکیج و مشاهده آنلاین مقاله

Massive biventricular thrombosis after transfemoral transcatheter aortic valve implantation

Mihaela Ioana Dregoesc, Mihnea Istrate, Irina Sandu, Adrian Corneliu Iancu

doi : 10.1093/eurheartj/ehac023

European Heart Journal, Volume 43, Issue 16, 21 April 2022, Page 1599

خرید پکیج و مشاهده آنلاین مقاله

Corrigendum to: PCSK9 inhibition in patients with heart failure â€“ neutral or harmful intervention?

doi : 10.1093/eurheartj/ehac089

European Heart Journal, Volume 43, Issue 16, 21 April 2022, Page 1568

خرید پکیج و مشاهده آنلاین مقاله

Corrigendum to: Proteomics for the prediction and prevention of atherosclerotic disease

doi : 10.1093/eurheartj/ehac130

European Heart Journal, Volume 43, Issue 16, 21 April 2022, Page 1581

خرید پکیج و مشاهده آنلاین مقاله